Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.


Clinical Trial Description

This is a Phase 1 dose-finding study of FT538 given in combination with a monoclonal antibody following lymphodepletion in subjects with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05069935
Study type Interventional
Source Fate Therapeutics
Contact DeShaun Noakes
Phone 858-875-1800
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date October 15, 2021
Completion date August 5, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04551885 - FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Phase 1
Recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Not yet recruiting NCT05054348 - Dose Escalation Study of IO-108 and IO-108+Pembrolizumab in Solid Tumors Phase 1
Recruiting NCT04020185 - Safety and Efficacy Study of IMSA101 in Refractory Malignancies Phase 1/Phase 2
Not yet recruiting NCT05055609 - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors Phase 1
Recruiting NCT04526106 - First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors Phase 1
Recruiting NCT04552288 - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Phase 2
Recruiting NCT04121442 - Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors Phase 1/Phase 2
Recruiting NCT04221204 - A Monotherapy in Subjects With Advanced Solid Tumors Phase 1
Terminated NCT03992326 - Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors Phase 1
Recruiting NCT04315246 - 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors Phase 1/Phase 2
Recruiting NCT04092673 - Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies Phase 1/Phase 2
Recruiting NCT04130516 - Phase 1 Study to Determine the MTD, Safety, Tolerability, PK and Preliminary Anti-tumor Effects of LNS8801alone and With Pembrolizumab Phase 1/Phase 2
Active, not recruiting NCT04041310 - Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors Phase 1
Not yet recruiting NCT04597541 - A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04585035 - Study to Evaluate D-1553 in Subjects With Solid Tumors Phase 1/Phase 2
Recruiting NCT04165330 - Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors Phase 1/Phase 2
Completed NCT04515043 - EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754) Phase 1
Recruiting NCT03600090 - Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer Phase 1
Not yet recruiting NCT05036226 - COAST Therapy in Advanced Solid Tumors and Prostate Cancer Phase 1/Phase 2